Improving Outcomes In Osteoporosis And Bone Health
Funder
National Health and Medical Research Council
Funding Amount
$348,494.00
Summary
Osteoporotic fractures are a common and increasing problem as the population ages. They are associated with increased risk of re-fracture and early death yet most patients remain untreated. This proposal will identify which fracture patients are at highest risk of re-fracture and premature death (b) identify whether osteoporosis treatment decreases this risk and (c) increase osteoporosis awareness and treatment uptake by general practitioners with an integrated fracture risk prediction tool.
I am an orthopaedic surgeon and clinician-scientist based at Sydney’s largest children’s hospital. My goal is to improve treatments for children with traumatic injuries and bone deformity. I have worked in bone research for over 20 years. My current research interests are finding new treatments for drug-resistant bacterial infections, treating genetic bone disease, and developing new medical devices to help children’s bones grow straight.
Delayed bone healing can be a considerable problem in both children and adults. Up to 10% of fractures fail to heal properly. An advanced understanding of the cellular responses in bone repair and their manipulation could improve the lives of many patients with orthopaedic problems. These studies will advance out knowledge of interventions to promote bone healing which could be translated rapidly into clinical care.
Using Mouse Models To Identify Better Therapies For Acute Leukemia And Myelodysplasia
Funder
National Health and Medical Research Council
Summary
Despite great advances in the understanding of the genes that cause cancers of the blood, cure rates for patients with acute leukemia, or a more indolent form called myelodyspslaia, has not improved significantly over the last 20 years, with the majority of patients dying from resistant or recurrent disease within 5 years. Our research will use mouse models of acute leukemia and myelodysplasia to identify the critical genetic pathways that drive these diseases and to design and test new therapie ....Despite great advances in the understanding of the genes that cause cancers of the blood, cure rates for patients with acute leukemia, or a more indolent form called myelodyspslaia, has not improved significantly over the last 20 years, with the majority of patients dying from resistant or recurrent disease within 5 years. Our research will use mouse models of acute leukemia and myelodysplasia to identify the critical genetic pathways that drive these diseases and to design and test new therapies that can be taken into clinical trials.Read moreRead less